Combined treatment with the glycine transporter-1-inhibitor Org24598, varenicline, and bupropion as a new pharmacological treatment concept for alcohol use disorder
Yasmin Olsson, Helga Lidö, Karin Ademar, Davide Cadeddu, Mia Ericson, Bo Söderpalm · FENS Forum 2024
Pharmacotherapy for Alcohol Use Disorder (AUD) may be improved by targeting mechanisms by which alcohol interferes with dopamine (DA) pathways in the reward circuitry. Alcohol acts on inhibitory glycine receptors (GlyR) in the nucleus Accumbens (nAc) and treatment with GlyR agonists raise basal DA, attenuate alcohol-induced DA release in the nAc and reduce alcohol intake in rats. Combined treatment with varenicline+bupropion produces additive effects on nAc DA output and abolishes the alcohol deprivation effect (ADE) in rats, predictive of clinical efficacy. This study examines whether the gly
ePoster · Neuroscience